Torque is developing a new class of Deep-Primed immune cell therapeutics for the treatment of cancer. It uses a technology platform to anchor powerful biotherapeutics - stimulatory cytokines, antibodies, and small molecules - directly to immune cells to direct and evoke immune cell responses, locally in the tumor microenvironment.